New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
08:38 EDTBIIB, XNPTXenoPort has positive readthroughs from clean Biogen label, says Wells Fargo
Wells Fargo believes that the benign FDA label for Biogen's (BIIB) Tecfidera indicates that regulators will have a favorable view of XenoPort's (XNPT) '829 treatment. The firm thinks that the label gives Biogen a better chance of maintaining exclusivity on its drug through 2028, possibly reducing the level of differentiation that XenoPort will need to demonstrate for '829. The firm maintains an Outperform rating on Xenoport.
News For XNPT;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use